| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany
Transfection of dendritic cells (DC) with tumor-derived RNA has recently been shown to elicit tumor-specific CTL capable of recognizing and lysing a variety of tumor cells. In our study we analyzed the induction of HLA class I- and II-restricted T cell responses against MCF-7 breast cancer cells. Using this approach we were able to elicit CD4- and CD8-mediated antitumor responses. The CTL specifically lysed MCF-7 cells and DC electroporated with MCF-7 RNA, but spared control cell lines. The specificity of the cytotoxic activity was confirmed in cold target inhibition assays and using mAbs blocking HLA class I molecules. Interestingly, these polyclonal cytotoxic T cells recognized selectively two epitopes derived from the MUC1 and Her-2/neu tumor Ags. The induced Th cells were found to be entirely HLA class II restricted and showed a significant cross-reactivity to a renal cell carcinoma cell line, similar to the results obtained with cytotoxic T cells.
This article has been cited by other articles:
|
|
 |
|
  H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Boss, F. Grunebach, K. Brauer, M. Hantschel, V. Mirakaj, T. Weinschenk, S. Stevanovic, H.-G. Rammensee, and P. Brossart Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen Clin. Cancer Res., June 1, 2007; 13(11): 3347 - 3355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Holtkamp, S. Kreiter, A. Selmi, P. Simon, M. Koslowski, C. Huber, O. Tureci, and U. Sahin Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells Blood, December 15, 2006; 108(13): 4009 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grunebach, V. Mirakaj, V. Mirakaj, M. R. Muller, T. Brummendorf, and P. Brossart BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia Cancer Res., June 1, 2006; 66(11): 5892 - 5900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Batchu, A. M. Moreno, S. M. Szmania, G. Bennett, G. C. Spagnoli, S. Ponnazhagan, B. Barlogie, G. Tricot, and F. van Rhee Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma Cancer Res., November 1, 2005; 65(21): 10041 - 10049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dorfel, S. Appel, F. Grunebach, M. M. Weck, M. R. Muller, A. Heine, and P. Brossart Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA Blood, April 15, 2005; 105(8): 3199 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al. Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nencioni and P. Brossart Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status Stem Cells, July 1, 2004; 22(4): 501 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells Blood, March 1, 2004; 103(5): 1763 - 1769. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
